Discarded Bile Fluid Detects Pancreatic and Bile Duct Cancers More Than a Year Before Standard Diagnosis

When gastroenterologists perform endoscopic procedures to investigate suspicious bile duct blockages, they routinely discard the bile fluid they collect. Now, researchers have demonstrated that this overlooked biofluid harbors critical cancer detection signals—and analyzing it costs far less than conventional genomic tests while potentially catching deadly cancers more than a year before standard diagnosis.

Turning Medical Waste Into Diagnostic Gold

Researchers at the First Hospital of Jilin University analyzed bile samples from 95 patients undergoing their first endoscopic retrograde cholangiopancreatography (ERCP) procedure for radiologically suspicious biliary strictures. Using ultra-low-pass whole-genome sequencing (ULP-WGS) at just 0.2× genomic coverage—a shallow sequencing depth that requires minimal DNA—they achieved 96% specificity in distinguishing benign from malignant strictures.

The method detected cancer DNA in 73% of confirmed malignancies overall, with particularly strong performance in cholangiocarcinoma cases (82% sensitivity). Among the 71 malignant cases identified—comprising 40 cholangiocarcinomas and 31 pancreatic ductal adenocarcinomas—the bile sequencing provided results a median of 38 days before conventional diagnosis. Seven patients received positive signals more than 100 days earlier than standard methods, with one remarkable case detecting cancer 499 days ahead of formal diagnosis.

This diagnostic lead time could prove clinically transformative. In pancreatobiliary cancers, where surgical resection offers the only curative option, a 38-day advantage may shift patients from unresectable to resectable disease status, directly impacting survival outcomes.

Economic Disruption in Liquid Biopsy

The study's economic implications may prove as significant as its clinical findings. The ultra-low-pass approach operates at approximately 130- to 215-fold lower cost than conventional 30–50× clinical whole-genome sequencing, requiring only 2 nanograms of starting DNA material. The researchers employed the open-source ichorCNA bioinformatics pipeline to detect copy-number alterations at a 10% tumor fraction threshold, identifying recurrent genomic signatures including losses of chromosomes 9p, 17p, and 18q, and gains of 7p, 7q, 8q, and 19q.

The method also demonstrated 86.4% accuracy in distinguishing cholangiocarcinoma from pancreatic ductal adenocarcinoma in a reference cohort, with 85.0% accuracy in validation—enabling tissue-of-origin classification before formal histology guides treatment planning.

By comparison, the conventional tumor marker CA19-9 achieved only 53% specificity in benign cases at a 44 U/mL threshold, frequently producing false positives due to cholestasis-induced marker elevation. A targeted 52-gene panel (Bilemut) detected mutations in 94.7% of malignant strictures but required more DNA and missed copy-number information captured by the whole-genome approach.

Prognostic Signals Beyond Detection

Beyond diagnostic classification, the bile genomic analysis provided prognostic stratification. Patients with combined tumor fraction positivity plus three or more gene mutations showed median overall survival of just 5.1 months compared to 13.7 months in other patients, with an adjusted hazard ratio of 2.51 (95% CI 1.22–5.14).

The findings address a critical clinical gap: approximately 73% of biliary strictures remain indeterminate after initial evaluation, as conventional tools like brush cytology and forceps biopsy frequently yield false negatives due to desmoplastic stroma that shields cancer cells from sampling. The bile sequencing method achieved 51% sensitivity even in these initially indeterminate cases.

The research, published in eGastroenterology by Rojo and colleagues, suggests a "waste-to-diagnosis" paradigm where procedure-specific biofluids collected during routine clinical care become sources of actionable genomic intelligence—potentially enabling liquid biopsy adoption in resource-constrained settings where cost has historically limited implementation.

Sources

1. Bile Sequencing Turns Discarded Fluid Into Early Cancer Clues — scienmag.com